Kytril, Sancuso(granisetron)
Granisol, Kytril, Sancuso, Sustol (granisetron) is a small molecule pharmaceutical. Granisetron was first approved as Kytril on 1993-12-29. It has been approved in Europe to treat neoplasms and vomiting.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Sancuso, Sustol (generic drugs available since 2007-12-31, discontinued: Granisol, Kytril)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Granisetron
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
HCPCS
Code | Description |
|---|---|
| J1626 | Injection, granisetron hydrochloride, 100 mcg |
| J1627 | Injection, granisetron, extended-release, 0.1 mg |
| Q0166 | Granisetron hydrochloride, 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 24 hour dosage regimen |
| S0091 | Granisetron hydrochloride, 1 mg (for circumstances falling under the medicare statute, use q0166) |
Clinical
Clinical Trials
88 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Vomiting | D014839 | HP_0002013 | R11.1 | 4 | 8 | 13 | 6 | 6 | 37 |
| Nausea | D009325 | HP_0002018 | R11.0 | 2 | 2 | 3 | 4 | 2 | 13 |
| Postoperative nausea and vomiting | D020250 | EFO_0004888 | — | 2 | 3 | 3 | 1 | 9 | |
| Neoplasms | D009369 | C80 | 1 | 2 | 5 | 1 | — | 9 | |
| Lymphoma | D008223 | C85.9 | — | 1 | — | 1 | 1 | 3 | |
| Leukemia | D007938 | C95 | — | — | — | 1 | 1 | 2 | |
| Prostatic neoplasms | D011471 | C61 | — | — | — | 1 | — | 1 | |
| Cholelithiasis | D002769 | EFO_0004799 | K80 | — | — | — | 1 | — | 1 |
| Temporomandibular joint disorders | D013705 | M26.6 | — | — | — | 1 | — | 1 | |
| Facial pain | D005157 | R51.9 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypotension | D007022 | EFO_0005251 | I95 | — | — | 1 | — | 1 | 2 |
| Gastroparesis | D018589 | EFO_1000948 | K31.84 | — | 1 | 1 | — | — | 2 |
| Postoperative complications | D011183 | — | — | 1 | — | — | 1 | ||
| Uterine cervical neoplasms | D002583 | — | — | 1 | — | — | 1 | ||
| Intraoperative complications | D007431 | — | — | 1 | — | — | 1 | ||
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | — | — | 1 | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 8 | — | — | — | — | 8 | ||
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | — | — | — | 1 | 2 |
| Pharmacokinetics | D010599 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | — | — | — | — | 2 | 2 |
| Brenner tumor | D001948 | — | — | — | — | 1 | 1 | ||
| Endometrioid carcinoma | D018269 | — | — | — | — | 1 | 1 | ||
| Fallopian tube neoplasms | D005185 | — | — | — | — | 1 | 1 | ||
| Cystadenocarcinoma | D003536 | — | — | — | — | 1 | 1 | ||
| Myelodysplastic syndromes | D009190 | D46 | — | — | — | — | 1 | 1 | |
| Myeloproliferative disorders | D009196 | D47.1 | — | — | — | — | 1 | 1 | |
| Neuroblastoma | D009447 | EFO_0000621 | — | — | — | — | 1 | 1 | |
| Plasma cell neoplasms | D054219 | — | — | — | — | 1 | 1 | ||
| Trophoblastic neoplasms | D014328 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | GRANISETRON |
| INN | granisetron |
| Description | 1-Methyl-N-{9-methyl-9-azabicyclo[3.3.1]nonan-3-yl}-1H-indazole-3-carboxamide is a member of indazoles and an aromatic amide. |
| Classification | Small molecule |
| Drug class | serotonin 5-HT3 receptor antagonists |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CN1C2CCCC1CC(NC(=O)c1nn(C)c3ccccc13)C2 |
Identifiers
| PDB | — |
| CAS-ID | 109889-09-0 |
| RxCUI | 26237 |
| ChEMBL ID | CHEMBL289469 |
| ChEBI ID | — |
| PubChem CID | 3510 |
| DrugBank | DB00889 |
| UNII ID | WZG3J2MCOL (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Sancuso - Cumberland Pharmaceuticals
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Sustol - HERON THERAPEUTICS, INC. /DE/
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,816 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
49,563 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more